Skip to main content

Angela Vidal Jordana

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Angela Vidal Jordana

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Caracterización estructural y funcional de la vía visual anterior en pacientes con esclerosis múltiple temprana (VISIONEM).

IP: Angela Vidal Jordana
Collaborators: Dulce María Moncho Rodríguez, Alex Rovira Cañellas, Manel Alberich Jordà, Neus Mongay Ochoa, Joaquin Castillo Justribo, Sergio Cabello
Funding agency: Instituto de Salud Carlos III
Funding: 48400
Reference: PI22/01589
Duration: 01/01/2023 - 31/12/2025

SGR-Cat 2021: Neuroimmunologia Clínica

IP: SGR-Cat 2021: Neuroimmunologia Clínica
Collaborators: Carlos Nos Llopis, SGR-Cat 2021: Neuroimmunologia Clínica, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, Samuel Sánchez Pous, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Edwin Roger Meza Murillo, Augusto Cesar Sao Aviles, Miguel Angel Robles Sanchez, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, Neus Mongay Ochoa, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 30/06/2025

Estudio de la vía visual en pacientes que presentan un síndrome clínico aislado, utilidad clínica y pronóstica

IP: Angela Vidal Jordana
Collaborators: Estudio de la vía visual en pacientes que presentan un síndrome clínico aislado, utilidad clínica y pronóstica, Joaquin Castillo Justribo, Georgina Arrambide García, Dulce María Moncho Rodríguez, Vanessa Carolina Thonon
Funding agency: Instituto de Salud Carlos III
Funding: 77440
Reference: PI17/02162
Duration: 01/01/2018 - 30/06/2022

Estudio del papel del inflamasoma en pacientes con esclerosis múltiple..

IP: Estudio del papel del inflamasoma en pacientes con esclerosis múltiple..
Collaborators: Jordi Rio Izquierdo, Angela Vidal Jordana, Luciana Midaglia Fernandez
Funding agency: Instituto de Salud Carlos III
Funding: 72600
Reference: PI16/00924
Duration: 01/01/2017 - 31/12/2020

Related news

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Maddalen Zufiaurre Seijo

Maddalen Zufiaurre Seijo

Research technician
Ophtalmology
Read more
Gloria Aparicio Español

Gloria Aparicio Español

Predoctoral researcher
Biomedical Research in Melanoma
Read more
Olalla Bagüés Bedoya

Olalla Bagüés Bedoya

Director/a Àrea
Human Resources Directorate
Read more
Maira Carolina Guzman Solano

Maira Carolina Guzman Solano

Maintenance staff and general services
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.